Table 4 The diagnostic performance of tRF-23-Q99P9P9NDD, CEA, CA199 and CA724 in differentiating early GC patients from healthy donors
| Â | SEN (%) | SPE (%) | ACCU (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|---|
tRF-23-Q99P9P9NDD | 0.60 (49/82) | 0.85 (101/119) | 0.75 (150/201) | 0.73 (49/67) | 0.75 (101/134) |
CEA | 0.51 (42/82) | 0.74 (88/119) | 0.65 (130/201) | 0.58 (42/73) | 0.69 (88/128) |
CA199 | 0.41 (34/82) | 0.77 (92/119) | 0.63 (126/201) | 0.56 (34/61) | 0.66 (92/140) |
CA724 | 0.46 (38/82) | 0.86 (102/119) | 0.70 (140/201) | 0.69 (38/55) | 0.70 (102/146) |
tRF-23-Q99P9P9NDD + CEA | 0.65 (53/82) | 0.64 (76/119) | 0.64 (129/201) | 0.55 (53/96) | 0.72 (76/105) |
tRF-23-Q99P9P9NDD + CA199 | 0.66 (54/82) | 0.72 (86/119) | 0.70 (140/201) | 0.62 (54/87) | 0.75 (86/114) |
tRF-23-Q99P9P9NDD + CA724 | 0.74 (61/82) | 0.75 (89/119) | 0.75 (150/201) | 0.67 (61/91) | 0.81 (89/110) |
tRF-23-Q99P9P9NDD + CEA + CA199 | 0.68 (56/82) | 0.55 (66/119) | 0.61 (122/201) | 0.51 (56/109) | 0.72 (66/92) |
tRF-23-Q99P9P9NDD + CEA + CA724 | 0.77 (63/82) | 0.55 (66/119) | 0.64 (129/201) | 0.54 (63/116) | 0.78 (66/85) |
tRF-23-Q99P9P9NDD + CEA + CA199 + CA724 | 0.78 (64/82) | 0.48 (57/119) | 0.60 (121/201) | 0.51 (64/126) | 0.76 (57/75) |